Trial Profile

A Phase 1 Dose Escalation and Expansion, Tolerability, Safety, Pharmacokinetics / Pharmacodynamics and Preliminary Efficacy Study of ZG0895.HCl in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZG0895-hydrochloride (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

04 Jun 2024 Preliminary (n=7; At data cut-off December 25, 2023) results assessing the safety, pharmacokinetics (PK) and antitumor activity of ZG0895 in patients with advanced solid tumors, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
04 Mar 2024 Status changed from not yet recruiting to recruiting.
20 Oct 2023 Planned initiation date changed from 1 Jul 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com